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Abstract
Background: Rubella infection can affect several organs and cause birth defects that are responsible for congenital
rubella syndrome (CRS). Congenital hearing loss is the most common symptom of this syndrome, occurring in
approximately 60% of CRS cases. Worldwide, over 100 000 babies are born with CRS every year. There is no specific
treatment for rubella, but the disease is preventable by vaccination. Since 1969, the rubella vaccine has been
implemented in many countries, but in Africa, only a few countries routinely immunize against rubella. The aim of
this study was to estimate the rate of infection from the wild-type rubella virus in São Tomé and Príncipe by
determining rubella seroprevalence with a DBS method. The goal of this study was to reinforce the need for
implementation of the rubella vaccine in this country. As secondary objectives, the validation of a DBS method was
first attempted and an association between seroprevalence and hearing loss was assessed.
Methods: We collected samples from individuals observed during humanitarian missions in São Tomé and Príncipe.
All individuals underwent an audiometric evaluation, and a drop of blood was collected for the dried blood spot (DBS).
We define two groups: the case group (individuals with unilateral or bilateral hearing loss (HL)) and the control group
(individuals with two normal ears). Patients were excluded if they suffered from conductive HL, if they showed
evidence of possible causes of HL, if they had developmental delay or if they refused to participate in the study.
Results: Among the 315 subjects, we found 64.1% individuals with IgG for the rubella virus, 32.1% without immunity
for the rubella virus and 3.8% who were borderline.
In the control group, 62.6% were positive for the rubella IgG, whereas in the case group, 72% were positive. Analyzing
both groups, with ages ranging from 2 to 14 years of age and from 15 to 35 years of age, we found a seroprevalence
of 50.3% to rubella in the younger group and 82.1% in the older group, with a significant difference between cases
and control group noted within the younger patients (p = 0.025).
Conclusions: Rubella is a disease that can be prevented. Rubella infections are still very common in São Tomé and
Príncipe, and women of child-bearing age are still at risk for rubella infection during pregnancy, justifying the urgency
of vaccination against rubella.
A statistically significant association between the group of children under 14 years of age with HL and immunity for
rubella was observed in this country, although this study did not allow us to establish a cause-effect relationship
between rubella infection and SNHL.
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Background
Primary rubella infection during pregnancy, particularly
during the first trimester, can affect several organs and
cause birth defects that are responsible for congenital
rubella syndrome (CRS) [1]. The most common defects
of CRS are hearing impairment (unilateral or bilateral
sensorineural), eye defects (e.g., cataracts, congenital
glaucoma, or pigmentary retinopathy), and cardiac de-
fects (e.g., patent ductus arteriosus or peripheral pul-
monic stenosis). Congenital hearing loss is the most
common sequela, occurring in approximately 60% of
cases, especially when infection occurs in the 4th month
of pregnancy [2]. In a Brazilian study, congenital rubella
was thought to be the cause of hearing loss in 32% of
patients with deafness [3], and in studies conducted in
sub-Saharan Africa, rubella was considered to be one of
the causes of HL [4].
The Global Measles and Rubella Strategic Plan (2012–
2020) included goals to eliminate rubella and CRS in at
least two WHO regions by 2015 as well as in at least five
WHO regions by 2020. However, in this plan, the
African region does not have a specific target. The num-
ber of rubella cases reported from 2000 to 2014 in-
creased in the African region (from 865 cases in seven
countries to 7402 cases in 44 countries). Although the
rubella vaccine has been implemented in many countries
since 1969, worldwide coverage is still a distant goal,
particularly in Africa, where only a few countries rou-
tinely immunize against rubella [5, 6].
The efficacy of the vaccine is approximately 95%, with-
out significant side effects [7]. In 2015, the Americas re-
gion was the world’s first region to eliminate rubella and
CRS. In Europe, all 53 Member States of the WHO
European Region committed in 2010 to the goal of inter-
rupting the endemic transmission of measles and rubella
by 2015, which was not yet achieved in all regions. How-
ever, many states, including Portugal, have already inter-
rupted the endemic transmission of rubella [8].
The São Tomé and Príncipe islands are within the At-
lantic in sub-Saharan Africa, located at the level of the
Equator. It is an underdeveloped country with few eco-
nomic resources that survives through external support,
including humanitarian service. As part of a humanitar-
ian project on the islands of São Tomé and Príncipe, the
“Health for All” system of Institute Marquês Valle Flor
(IMVF) has been implemented to improve the primary
and secondary health care of the population. This pro-
ject includes doctors of several specialties, including
otolaryngology.
During these tasks, an increased prevalence of sensori-
neural hearing loss (SNHL) cases was initially noted,
particularly in the younger age group [9]. CRS cannot be
excluded as a possible etiology of SNHL and is one of
several possible causes.
The epidemiology of rubella is not known in this
country, and there is no vaccine implementation [10]
nor is there the possibility of diagnosis through labora-
tory tests.
The aim of this study is to estimate the rate of infected
people with wild-type rubella virus in São Tomé and
Príncipe by determining rubella seroprevalence through
the DBS method to reinforce the need for vaccine imple-
mentation in this country. As secondary objectives, the
validation of a DBS method was first attempted and an
association between seroprevalence and hearing loss was
also evaluated.
Methods
Subjects
The samples studied were collected between January and
May of 2014 from individuals who presented for an
audiology consultations at the Hospital Ayres de
Menezes on São Tomé Island and the Hospital Dr Man-
uel Quaresma Dias da Graça on Principe Island during
humanitarian missions. Samples were also collected
from students and workers from a hotel. All participants
in the study were natives and residents of the islands. In
total, we analyzed 315 samples collected from individ-
uals 2 to 35 years old. Of these, 171 individuals were fe-
male and 144 were male. All individuals underwent
audiometric evaluation (tonal audiogram or auditory
brainstem response measurements) according to the de-
gree of collaboration, having adapted the results of the
auditory brainstem response (ABR) to audiometric
thresholds according to standards [11].
We defined two groups based on the WHO classifica-
tion [12]. The case group was composed of individuals
with hearing loss, in which we included individuals with
unilateral HL or both ears with HL. The control group
included individuals with two normal ears.
All patients answered a questionnaire about self-
reported HL and clinical history. There are no clinical
registries about these patients in any hospital from São
Tomé or Príncipe.
Patients were excluded if they suffered from conduct-
ive deafness, showed evidence of possible causes of HL,
had developmental delay, or did not give consent to par-
ticipate in the study.
In addition to the audiometric evaluation, a drop of
blood was collected via venous or capillary puncture and
blotted onto filter paper. After collection, the blood
spots were dried at room temperature for 24 h (Dried
blood spot—DBS). The IgG measurement was carried
out in Portugal after 9 months (during which the sam-
ples were stored at room temperature).
The project was submitted to and approved by the
Medical Ethics Committee of STP and Ethics Research
Committee NMS|FCM-UNL (n°02/2014/CEFCM). The
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Ethics Research Committee is aligned with the Declar-
ation of Helsinki for the Protection of Human Subjects.
A full consent process was applied for all participants.
Consent to use the survey data was also obtained.
Technical validation of the rubella IgG determination
The procedure of IgG determination from DBS was vali-
dated and optimized by two approaches: 1) First, sam-
ples were collected from 20 pregnant women at the
Hospital da Luz, Portugal. We simultaneously collected
blood samples for DBS and for serum. The specificity
and sensitivity of the IgG determination from DBS were
evaluated compared to the standard method (IgG deter-
mination from serum). 2) Second, 15 DBS samples were
collected in 10 children between 1 and 10 years of age
(who were vaccinated against rubella) and 5 children be-
tween 9 and 12 months of age (who were not vaccinated
against rubella). In this group, IgG determination from
DBS was correlated with the immune status (vaccinated
/ unvaccinated).
The extraction protocol for IgG in DBS was tested
with three different volumes of diluent (200 μL, 400 μL,
and 800 μL) in this validation step, while the protocol
for the determination of the serum IgG was recom-
mended by the SERION ELISA classic rubella virus IgG
kit. Both the extraction and IgG ELISA protocols are de-
scribed below.
Rubella IgG determination from the São Tomé and
Príncipe population
Rubella IgG extraction: For the IgG extraction, we added
400 μL of SERION ELISA kit dilution solution to ¼ of
the DBS, corresponding to 32 mm2. The extraction was
carried out for 60 min at 600 rpm at room temperature
and 18 h at 4 °C.
Rubella IgG determination: The SERION ELISA classic
rubella virus IgG kit was used for this determination.
We performed the protocol recommended by SERION.
Briefly, 100 μL of the control, standard and extracted
samples were pipetted into a 96 well microplate (only
one sample per patient was tested). The microplate was
then incubated at 37 °C for 60 min in a humid chamber
and washed 3 times with wash solution (300 μl). Then,
the IgG conjugate (100 μl) was added and the microplate
was incubated under the same conditions, after which
the washing process was repeated. Subsequently, the
substrate (100 μl) was added and the incubation process
was repeated. Finally, we added a stop solution (100 μl),
and the optical density was read at 415 nm against
630 nm. The optical densities were converted into UI
through the Serion Activity V11 program, with the fol-
lowing interpretation: negative: <10UI; borderline; 10–
15UI;positive >15UI.
The results were interpreted according to the algo-
rithm shown in Fig. 1.
Statistical processing of the data
Sample descriptions were made using descriptive statis-
tics, considering the frequency analysis, means and
standard deviations (SDs).
To study the association between IgG rubella in the
case/ control group and each of the following parame-
ters, age group, district origin, oral language, gender and
HL, the chi-square test was used by Monte Carlo
Simulation.
To identify the risk factors of HL, we adopted a Binary
Logistic Regression, where HL is a response variable.
The independent variables were the IgG rubella and age
groups.
All analyses were performed using the Statistical Pack-
age for the Social Sciences for Mac version 20.0 (SPSS).
Results
Technical validation of the rubella IgG determination
The sensitivity and specificity for each of the different
volumes of diluent tested, when compared with the
standard method were, 100 and 50% (200 μL), 89 and
100% (400 μL) and 72 and 100% (800 μL). According to
these results, a volume diluent of 400 μL was chosen for
the determination of Rubella IgG in the São Tomé and
Príncipe populations.
The DBS method also showed a good correlation
(100%) with the immune status (vaccinated/unvaccin-
ated). The ten vaccinated children were positive for the
IgG while the five unvaccinated children were negative
for IgG.
Rubella IgG determination from São Tomé and Príncipe
population
We evaluated 315 subjects (Table 1), from 2 to 35 years
of age, of whom 144 (45.7%) were men and 171 (54.3%)
were women, with a mean age of 17.36 ± 9.734 years.
Among the 315 subjects, we found 202 (64.1%) indi-
viduals with IgG for the rubella virus. Of these, 101
(32.1%) did not have immunity to rubella and 12 (3.8%)
were borderline. Borderline cases were excluded from
the study.
In the sample, we did not find any statistical signifi-
cance for gender (p = 0.391), resident district (p = 0.061,
or chi-squared test by Monte Carlo simulation), family
history of HL (p = 0.207), or consanguinity (p = 0.461).
We established two groups concerning hearing status:
a control group with patients with normal hearing in
both ears and a case group with at least one ear with
sensorineural hearing loss (SNHL).
In the control group, we found 62.6% of positive im-
munity to rubella, whereas in the case group, positive
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immunity was 72%. There was not a significant differ-
ence between the case and control groups (p = 0.085).
Analyzing both the 2-to-14 years of age group and the
15-to-35 years of age group, we found a seroprevalence
of 50.3% to rubella in the younger group and 82.1% in
the older group, with a significant difference between
the case and control groups within the younger group
(p = 0.025) but not within the older group (p = 0.528)
(Table 2).
By applying the binary logistic regression model, posi-
tive immunity to rubella was identified as a risk factor
for HL (Table 3). Positive immunity to rubella almost
doubled the risk of HL (OR = 1.776; CI 95% [1.050–
3.004]) when analyzed with the age groups, but without
any statistical significance in these age groups. There-
fore, immunity to rubella was associated with HL.
A higher prevalence of “no oral language” was found
in the case group compared to the control group (p =
0.0001).
Discussion
Since their first diagnostic application almost five de-
cades ago, DBSs have been employed in many research
areas and in clinical applications for several viruses, in-
cluding Human immunodeficiency virus, Hepatitis C
virus, Hepatitis B virus, Hepatitis A virus, Hepatitis E
virus, Human cytomegalovirus, Epstein-Barr virus, Her-
pes simplex viruses, and measles-, dengue- and rubella-
viruses. Although it is not expected that current wet
sampling techniques will be replaced by the use of DBSs,
this method allows sampling in individuals and settings
with difficult access and/or a lack suitable storage facil-
ities [13]. Indeed, the DBS method is a minimally inva-
sive and more economic sampling method that is readily
available and that facilitates sample collection and stor-
age. It involves the collection of capillary blood from a
fingerstick onto a protein-saver card, which is then air-
dried and stored until processing. DBS samples can be
stored and transported for testing at a later date, which
may also provide enhanced surveillance in resource-
limited settings [14].
In the current study, the accuracy of the IgG deter-
mination from DBS samples was assessed before the de-
termination of rubella seroprevalence. The main
limitations of this evaluation were the number of sam-
ples tested, which were lower than initially planned, and
the fact that immunity by vaccination may not be similar
to immunity by natural infection. In fact, children from
São Tomé and Príncipe had higher average IgG results
than Portuguese children (respectively 89.35 and 50.9; p
= 0.034, data not presented). Despite these limitations,
the results suggest that the determination of IgG for the
rubella virus in DBS had a good correlation with the
standard method. These results are in accordance with a
previous publication that showed no significant differ-
ences in the antibody concentrations in paired serum-
Fig. 1 Algorithm for the interpretation of the results. The results are expressed in international units (U/I)
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DBS samples, [15] although in our study, only the quali-
tative correlation is presented. Actually, quantitative
DBS samples were also previously tested for the diagno-
sis of rubella during an outbreak, with an excellent cor-
relation with the determination in serum, provided that
the DBS indeterminate results were positive [16]. In
addition, this methodology was used for the diagnosis of
congenital rubella syndrome in another study, by detect-
ing rubella IgM and IgG (the last in ≥ 6 months old in-
fants) in DBS, although in this study, the comparison
was not performed with the reference sample, serum,
but with oral fluid samples [17]. Therefore, using DBS
for serology determinations seems to be an appropriate
and useful approach, particularly in countries where rou-
tine immunization is not performed, to estimate the rate
of infection with the wild-type rubella virus.
The prevalence of IgG in the population from São
Tomé and Príncipe of 303 individuals from 2 to 35 years
of age was 66.7%, confirming that rubella infections are
still very common in this country. In the group of chil-
dren under 14 years of age, the prevalence of immunity
to rubella was 50.3% (74/147 subjects), while in the age
group between 15 and 35 years of age, the prevalence in-
creased by up to 82.1% (128/156 subjects. This increase
Table 1 General characteristics of the São Tomé and Príncipe population
Total
(n = 303)
Control Gr
(171–56.4%)
Case Gr
(132–43.6%)
p-Value
Age range 0.359
[2–14]
[15–35]
147 (48.5%)
156 (51.5%)
79 (46.2%)
92 (53.8%)
68 (51.5%)
64 (48.5%)
Mean Age SD 17.31 ± 9.722 17.73 ± 9.729 16.77 ± 9.723
Gender 0.391
Male
Female
137 (45.2%)
166 (54.8%)
81 (47.4%)
90 (52.6%)
56 (42.4%)
76 (57.6%)
Resident District 0.061*
Água Grande
Mezochi
Cantagalo
Caué
Lemba
Lobata
Príncipe
174 (57.4%)
47 (15.5%)
17 (5.6%)
23 (7.6%)
6 (2%)
19 (6.3%)
17 (5.6%)
110 (64.3%)
17 (9.9%)
8 (4.7%)
12 (7%)
3 (1.8%)
11 (6.4%)
10 (5.8%)
64 (48.5%)
30 (22.7%)
9 (6.8%)
11 (8.3%)
3 (2.3%)
8 (6.1%)
7 (5.3%)
Spoken Language 0.0001
Yes
No
Undefined
242 (86.7%)
37 (13.3%)
24
161 (97.6%)
4 (2.4%)
6
81 (71.1%)
33 (28.9%)
18
Family History of HL 0.207
Yes
No
Missing
52 (17.5%)
245 (82.5%)
6
33 (20%)
132 (80%)
6
19 (14.4%)
113 (85.6%)
Consanguinity 0.461
Yes
No
Missing
7 (2.4%)
285 (97.6%)
11
3 (1.8%)
162 (98.2%)
6
3 (3.1%)
123 (96.9%)
5
Rubella IgG 0.085
Positive
Negative
Borderline
202 (66.7%)
101 (33.3%)
12
107 (62.6%)
64 (37.4%)
95 (72%)
37 (28%)
Abbreviations: SD standard deviation
*Chi-square Test by Monte Carlo Simulation; Bold: Total sample; Italic: p-Value; Italic bold: statistic significant p-Value
Table 2 Sample description of the case/control group and
rubella IgG in the different age ranges
Total
(n = 303)
IgG Pos
(117–58.8%)
IgG Neg
(82–41.2%)
p-Value
Age range 0.025
[2–14] 147 (48.5%) 74 73
Control group
Case group
79
68
33 (44.6%)
41 (55.4%)
46 (63%)
27 (37%)
Age range 0.528
[15–35] 156 (51.5%) 128 28
Control group
Case group
92
64
74 (57.8%)
54 (42.2%)
18 (63.3%)
10 (35.7%)
Bold: Total sample; Italic: p-Value; Italic bold: statistic significant p-Value
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suggests that women of child-bearing age are still suffer-
ing from rubella primary infections, and 18% of these
women are at risk for rubella infection during pregnancy
and subsequent CRS/birth defects in their children.
Interestingly, an association between seroprevalence
and SNHL was observed in the younger group (children
<14 years, p = 0.025), but in the older group (>14 years,
p = 0.528). While congenital rubella infection is a known
cause of deafness, the relationship between postnatal ac-
quired infection and hearing loss is not proven, although
a few reports suggest that it may occasionally occur [18,
19]. In this study, it was not possible to conclude how
many cases of HL are attributable to rubella infection
because the time of infection cannot be determined.
Therefore, the rate of positive IgG infection resulting from
congenital infections is not known, although the probabil-
ity of infection during the gestational period is higher in
the youngest group. The detection of rubella IgM in DBS
from newborns will help to clarify this key question. This
will be part of a future project of our team.
The development of oral language is dependent of the
hearing status. Therefore, we found an expected higher
prevalence of “no oral language” in the case group than
in the control group.
According to the CDC, the rubella vaccine may be ad-
ministered in combination with the mumps vaccine or
the measles and mumps vaccine [20]. These should be
administered at 12 to 15 months of age, with a second
dose given at 4 to 6 years of age. However, given the
need to control the transmission of rubella during preg-
nancy, vaccination of female children between 10–12
years of age and women of childbearing age is also rec-
ommended. The rubella vaccine has been shown to be
effective without significant side effects and should thus
be quickly implemented in the population of São Tomé
and Príncipe as well as other African countries in which
the rubella vaccine is not currently implemented and
where there is an increase of SNHL [4].
The combined vaccine with the measles and mumps
vaccine would be advantageous because these two
pathologies can also unleash SNHL in the course of the
disease [20].
Conclusion
Rubella is a preventable disease. Currently, most of the
African countries do not use this vaccine.
Rubella infections are still very common in São Tomé
and Príncipe, and women of child-bearing age are still at
risk of rubella infection during pregnancy and subse-
quent CRS/birth defects of their children, justifying the
urgency of vaccination against rubella.
According to the results obtained, a statistically signifi-
cant association between the group of children under
14 years of age with SNHL and immunity for rubella
was observed in this country. However, this study did
not permit us to establish a cause-effect relationship be-
tween rubella infection and SNHL. Therefore, another
study aiming to screen newborns for congenital rubella
infection and to follow them for audiometric assessment
is critical to determine the real impact of this infection
in this African country.
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